Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees
Nicole L. Yates, Allan C. deCamp, Bette Korber, et al.
Journal of Virology (2018) Vol. 92, Iss. 8
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Glycosylation in health and disease
Colin Reily, Tyler J. Stewart, Matthew B. Renfrow, et al.
Nature Reviews Nephrology (2019) Vol. 15, Iss. 6, pp. 346-366
Open Access | Times Cited: 1587
Vaccination induces HIV broadly neutralizing antibody precursors in humans
David J. Leggat, Kristen W. Cohen, Jordan R. Willis, et al.
Science (2022) Vol. 378, Iss. 6623
Open Access | Times Cited: 150
3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope–specific plasma cells and humoral immunity in nonhuman primates
Sudhir Pai Kasturi, Mohammed Ata Ur Rasheed, Colin Havenar‐Daughton, et al.
Science Immunology (2020) Vol. 5, Iss. 48
Open Access | Times Cited: 117
Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk
Scott D. Neidich, Youyi Fong, Shuying S. Li, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 11, pp. 4838-4849
Open Access | Times Cited: 103
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study
Lindsey R. Baden, Daniel J. Stieh, Michal Sarnecki, et al.
The Lancet HIV (2020) Vol. 7, Iss. 10, pp. e688-e698
Open Access | Times Cited: 78
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates
Kevin O. Saunders, Norbert Pardi, Robert Parks, et al.
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 70
HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge
Andrew Jones, Xiaoying Shen, Korey A. Walter, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 63
Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa
Glenda Gray, Ying Huang, Nicole Grunenberg, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 510
Open Access | Times Cited: 63
Absolute quantitation of binding antibodies from clinical samples
Chan Tang, Annemiek Verwilligen, Jerald Sadoff, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 5
A Pentavalent HIV-1 Subtype C Vaccine Containing Computationally Selected gp120 Strains Improves the Breadth of V1V2 Region Responses
Xiaoying Shen, Bette Korber, Rachel L. Spreng, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 133-133
Open Access
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
Fatima Laher, Zoe Moodie, Kristen W. Cohen, et al.
PLoS Medicine (2020) Vol. 17, Iss. 2, pp. e1003038-e1003038
Open Access | Times Cited: 39
Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial
Ian Frank, Shuying S. Li, Nicole Grunenberg, et al.
The Lancet HIV (2024) Vol. 11, Iss. 5, pp. e285-e299
Closed Access | Times Cited: 4
Robust antibody and cellular responses induced by DNA-only vaccination for HIV
Stephen C. De Rosa, Srilatha Edupuganti, Yunda Huang, et al.
JCI Insight (2020) Vol. 5, Iss. 13
Open Access | Times Cited: 34
Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV
Susan Zolla‐Pazner, Raymond A Alvarez, Xiang‐Peng Kong, et al.
Current Opinion in HIV and AIDS (2019) Vol. 14, Iss. 4, pp. 309-317
Open Access | Times Cited: 34
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein
Mina C. Hosseinipour, Craig Innes, Sarita Naidoo, et al.
Clinical Infectious Diseases (2020) Vol. 72, Iss. 1, pp. 50-60
Open Access | Times Cited: 31
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study
Daniel J. Stieh, Dan H. Barouch, Christy Comeaux, et al.
The Journal of Infectious Diseases (2022) Vol. 227, Iss. 8, pp. 939-950
Open Access | Times Cited: 17
Design and characterization of a self-assembling protein nanoparticle displaying HIV-1 Env V1V2 loop in a native-like trimeric conformation as vaccine antigen
Christopher P. Karch, Hongjun Bai, Oscar B. Torres, et al.
Nanomedicine Nanotechnology Biology and Medicine (2018) Vol. 16, pp. 206-216
Closed Access | Times Cited: 29
Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway
Dieter Mielke, Gama Bandawe, Justin Pollara, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 27
HIV vaccine delayed boosting increases Env variable region 2–specific antibody effector functions
David Easterhoff, Justin Pollara, Kan Luo, et al.
JCI Insight (2020) Vol. 5, Iss. 2
Open Access | Times Cited: 26
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial
Zoe Moodie, Erica Andersen‐Nissen, Nicole Grunenberg, et al.
PLoS Medicine (2024) Vol. 21, Iss. 3, pp. e1004360-e1004360
Open Access | Times Cited: 2
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans
Lue Ping Zhao, Andrew Fioré-Gartland, Lindsay N. Carpp, et al.
PLoS ONE (2020) Vol. 15, Iss. 1, pp. e0226803-e0226803
Open Access | Times Cited: 23
Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1
Matthew Zirui Tay, Erika L. Kunz, Aaron Deal, et al.
Journal of Virology (2019) Vol. 93, Iss. 7
Open Access | Times Cited: 20
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates
Kevin O. Saunders, Norbert Pardi, Robert Parks, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 20
New insights into pathogenesis point to HIV-1 Tat as a key vaccine target
Barbara Ensoli, Sonia Moretti, Alessândra Borsetti, et al.
Archives of Virology (2021) Vol. 166, Iss. 11, pp. 2955-2974
Open Access | Times Cited: 16
Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response
LaTonya D. Williams, Xiaoying Shen, Sheetal Sawant, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 5, pp. e1011359-e1011359
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top